期刊文献+

Efficacy of Lidan Tang on high-fat-diet induced gallstone in mice and possible mechanism 被引量:5

原文传递
导出
摘要 OBJECTIVE:To investigate efficacy of Lidan Tang(LDT)on gallstone induced by high fat diet in mice,and to study its underlying mechanism.METHODS:Mice were fed with high fat diet every day and treated with LDT(9.01 times of human clinic dosage).Mice were randomly divided into 6 groups as control group,gallstone model group(high-fat diet),positive control ursodeoxycholic acid(UDCA)group(80 mg·kg^-1·d^-1,i.g.),LDT low dose group(6 kg/d,i.g.),LDT middle dose group(12 kg/d,i.g.),and LDT high dose group(24 kg/d,i.g.).The whole experiment was lasted for 4 weeks.The levels of ALT,AST,LDH,CHO,HDL-C and LDL-C in serum were measured,the pathological sections were observed by hematoxylin-eosin staining,the activities of antioxidant enzymes were measured by kits,and the proteins related to oxidative stress and lipid transport were detected by Western blot analysis.RESULTS:LDT could significantly reduce the contents of ALT and AST in serum and improve the pathological tissue of liver.LDT could significantly reduce the content of MDA and LPO,and increase the level of GSH and GSH-PX in liver tissue.The data of Western blot showed that LDT had antioxidant effect promoting Keap1/Nrf2 pathway and regulated the process of lipid transport,which was statistically significant.In addition,LDT treatment inhibited the expression of ATP-binding cassette transports ABCG5/8 in liver,and reduced cholesterol transport from the hepatocytes to the gallbladder.CONCLUSION:LDT has protective effect on gallstones induced by high fat diet in mice,which might be based on the protective effect on liver,including enhancing the antioxidant capacity of liver and reducing the production of lipid peroxides.
出处 《Journal of Traditional Chinese Medicine》 SCIE CAS CSCD 2020年第4期584-592,共9页 中医杂志(英文版)
基金 the National Natural Science Foundation of China(the Mechanism of Treating Cholelithiasis Based on the Theory of Biliary Diseases Treated by Differentiating Syndromes of the Liver,No.81473570) the Drug Innovation Major Project(No.2018ZX09711001-002-007,2018-ZX09711001-003-005,2018ZX09711001-009-013) Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study(BZ0150)。
  • 相关文献

参考文献1

共引文献8

同被引文献58

引证文献5

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部